Lemmens Liesbeth
COPE-Unlimited, Kermt-Hasselt, Belgium; Tel.: +32 0 496101965.
Lung Cancer Manag. 2016 Apr;5(1):29-41. doi: 10.2217/lmt.15.33. Epub 2015 Nov 3.
Nintedanib plus docetaxel is approved in the EU for the treatment of patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy. Nintedanib in combination with docetaxel has a manageable safety profile in adenocarcinoma NSCLC patients. The most frequent adverse events (AEs) associated with nintedanib are gastrointestinal events and elevations in liver enzymes. Most AEs can be managed effectively with supportive treatment or a dose reduction and do not require permanent discontinuation. This article aims to provide practical guidance on management of AEs and how patients should be assessed for AEs prior to initiation and regularly monitored throughout treatment. Patients and their carers can play an important role in recognizing and managing AEs and should be given the relevant information, skills and confidence to achieve this.
在欧盟，尼达尼布联合多西他赛被批准用于治疗一线化疗后出现的局部晚期、转移性或局部复发性腺癌组织学非小细胞肺癌（NSCLC）患者。尼达尼布联合多西他赛在腺癌NSCLC患者中具有可控的安全性。与尼达尼布相关的最常见不良事件（AE）是胃肠道事件和肝酶升高。大多数AE可通过支持治疗或剂量减少有效管理，无需永久停药。本文旨在为AE的管理提供实用指导，以及在开始治疗前应如何评估患者的AE，并在整个治疗过程中进行定期监测。患者及其护理人员在识别和管理AE方面可发挥重要作用，应给予他们相关信息、技能和信心以实现这一点。
